이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

2026년부터 2029년까지 오존 치료를 통한 완화 치료를 위해 만성 통증 클리닉에 의뢰된 환자들. (EPOOzo-2)

2026년 9월 22일 업데이트: Bernardino Clavo, MD, PhD

2026년부터 2029년까지 오존 요법을 통한 완화 치료를 위해 만성 통증 클리닉에 의뢰된 환자들에 대한 전향적 관찰 연구. 전향적 연구 EPOOzo-2.

The main objective of this study is to analyze the impact on the health-related quality of life of patients with refractory symptoms who have been referred to the Dr. Negrín University Hospital Chronic Pain Unit for adjuvant palliative treatment with ozone therapy between January 2026 and December 2029. Additionally, the study aims to evaluate several specific symptoms, hyperspectral and thermal images, non-invasive clinical parameters related to the Autonomic Nervous System (such as heart rate variability, electrochemical skin conductance, and vibration perception thresholds), oxidative stress and inflammatory parameters, and gut microbiota composition.

연구 개요

상태

모병

정황

개입 / 치료

상세 설명

Patients are referred to the Chronic Pain Unit in the absence or failure of standard treatment, or when the standard treatment is associated with high morbidity or high risk. Frequently, these patients present alterations in self-perceived health-related quality of life (HRQoL), anxiety, depression, and other symptoms such as radiation-induced pelvic toxicity or chemotherapy-induced peripheral neuropathy (CIPN).

This prospective observational study (EPOOzo-2) aims to evaluate the effect of adjuvant symptomatic/palliative ozone therapy on HRQoL and potential changes from baseline. Specifically, it incorporates new non-invasive technologies to objectively assess microcirculation, neuropathy and autonomic regulation.

Main Objectives:

1. Analyze the impact on HRQoL of patients with refractory symptoms treated with ozone.

Secondary Objectives: Depending on the clinical case, analyze the impact of ozone treatment on: 2. Anxiety and depression. 3. Treated symptoms (e.g., pain, paresthesia). 4. Fatigue. 5. Toxicity grade (in cancer patients). 6. Non-invasive clinical parameters related to the Autonomic Nervous System (central and peripheral) and somatosensory function. 7. Biochemical parameters and gut microbiome analysis (in patients with systemic/rectal ozone).

Methodology: Prospective and observational study of patients referred for symptomatic/palliative ozone therapy between January 2026 and December 2029.

Assessments at weeks: 0 (baseline), 16 (end of O3/O2 treatment), 28 (12 weeks after the end of ozone), and 40 (24 weeks after the end of ozone).

연구 유형

관찰

등록 (추정된)

120

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Francisco Rodríguez-Esparragón, BSc, PhyD
  • 전화번호: +34 928449288
  • 이메일: afrodesp@gmail.com

연구 장소

    • Las Palmas
      • Las Palmas de Gran Canaria, Las Palmas, 스페인, 35019
        • 모병
        • Dr. Negrín University Hospital
        • 연락하다:
          • Francisco Rodríguez-Esparragón, BSc, PhyD
          • 전화번호: +34 928449288
          • 이메일: afrodesp@gmail.com
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

샘플링 방법

비확률 샘플

연구 인구

Patients submitted to the Chronic Pain Unit of the Hospital Universitario de Gran Canaria Dr. Negrín, between January 2026 and December 2029, for symptomatic/palliative treatment with ozone therapy because standard treatment does not exist, it has been unsuccessful, or it is associated with high risk or high morbidity.

설명

Inclusion Criteria:

  • 1. Adults ≥ 18 years old.
  • 2. Patients referred to the Chronic Pain Unit of the Dr. Negrín University Hospital for symptomatic/palliative treatment with ozone therapy because conventional treatment does not exist, has failed, has offered insufficient results, or is associated with high risk/morbidity.
  • 3. After evaluation of symptoms and patients, it exists a potential benefit of adding ozone treatment to the current treatment.
  • 4. Patients have no contraindications for ozone treatment.
  • 5. Patients must sign the specific Informed Consent for this study and for the ozone treatment.

Exclusion Criteria:

  • 1. Age < 18 years old.
  • 2. Psychiatric illness or social situations that would limit compliance with study requirements.

Contraindication or disability to attend scheduled treatments.

  • 3. Contraindication or disability to attend scheduled treatments.
  • 4. Uncontrolled clinical conditions (e.g., severe heart failure, massive hemorrhage, status epilepticus).
  • 5. Life expectancy < 6 months.
  • 6. Known allergy to ozone.
  • 7. Hemochromatosis (for systemic ozone treatment).
  • 8. Pregnancy (for systemic ozone treatment).
  • 9. Significant Glucose-6-Phosphate Dehydrogenase deficiency (Favism) (for systemic ozone treatment).
  • 10. Patients who do not meet the inclusion criteria.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 관찰 모델: CASE_ONLY
  • 시간 관점: PROSPECTIVE

코호트 및 개입

그룹/코호트
개입 / 치료
Ozone Group

Patients with refractory symptoms referred for palliative treatment with ozone therapy between 2026 and 2029.

Systemic (rectal, autohemotherapy) and/or local ozone administration (cutaneous, intravaginal, intravesical). Dosage, frequency, and duration will depend on the symptoms treated and clinical evolution. Usually planned 40 sessions over 4 months.

다른 이름들:
  • 오존 치료

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At the end of ozone therapy (approx. week 16).

2차 결과 측정

결과 측정
측정값 설명
기간
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "EQ-5D-5L" Questionnaire (at 24 weeks after the end of ozone therapy).
기간: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of 5 physical and emotional items scored in five levels, plus a Visual Analog Scale (EQ-VAS) from 0 (worst health) to 100 (best health).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 12 weeks after the end of ozone therapy).
기간: At 12 week after the end of ozone therapy (approx. week 28).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 12 week after the end of ozone therapy (approx. week 28).
Change from Baseline in Anxiety and Depression Levels (HAD Scale) (at 24 weeks after the end of ozone therapy).
기간: At 24 week after the end of ozone therapy (approx. week 40).

Hospital Anxiety and Depression Scale (HADS). Scores range from 0 to 21 for each subscale, where higher scores indicate worse anxiety or depression.

At 24 week after the end of ozone therapy (approx. week 40).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At the end of ozone therapy (approx. week 16).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Health-Related Quality of Life by the "QLQ-C30" Questionnaire (only in cancer patients). (At 24 weeks after the end of ozone therapy).
기간: At 24 weeks after the end of ozone therapy (approx. week 40).

The EORTC QLQ-C30 is a 30-item questionnaire that includes five functional scales (physical, role, emotional, cognitive, and social), three symptom scales (fatigue, nausea and vomiting, and pain), a global health status scale, and several single items. Scores are transformed to a 0-100 scale. For functional and global health scales, higher scores represent better functioning or quality of life. For symptom scales/items, higher scores indicate greater symptomatology or problems

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At the end of ozone therapy (approx. week 16).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Fatigue (Chalder Fatigue Scale and/or EORTC QLQ-FA12 for cancer patients) (at 24 weeks after the end of ozone therapy).
기간: At 24 weeks after the end of ozone therapy (approx. week 40).

Assessed using the Chalder Fatigue Scale (CFQ-11) and/or EORTC QLQ-FA12 for cancer patients. Higher scores indicate greater fatigue

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Pain Score (Visual Analog Scale), (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At the end of ozone therapy (approx. week 16).
Change from Baseline in Pain Score (Visual Analog Scale), (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Pain Score (Visual Analog Scale), (at 24 weeks after the end of ozone therapy).
기간: At 24 weeks after the end of ozone therapy (approx. week 40).

Self-reported evaluation of pain severity using a Visual Analog Scale (VAS), scored from 0 ("No pain") to 10 ("Pain as bad as you can imagine").

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At the end of ozone therapy (approx. week 16).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in the grade of toxicity secondary to cancer-treatment (if applicable) according to the CTCAE v5.0 scale, (at 24 weeks after the end of ozone therapy).
기간: At 24 weeks after the end of ozone therapy (approx. week 40).

Grade of toxicity secondary to cancer-treatment according to the CTCAE v5.0 (Common Terminology Criteria for Adverse Events from the National Cancer Institute) scale. Each toxicity is usually scored from 0 (asymptomatic or mild symptoms) to 5 (death).

At 24 weeks after the end of ozone therapy (approx. week 40).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Electrochemical Skin Conductance (Sudoscan), (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive evaluation of sudomotor function (small fiber neuropathy assessment). Measured in microsiemens (µS) on hands and feet using SUDOSCAN technology.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Vibration Perception Thresholds (Multifrequency Vibrometry), (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of large fiber nerve function using the VibroSense Meter II. Measures perception thresholds at different frequencies (e.g., 4Hz to 500Hz).

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Postural Stability (Equilibrium Platform), (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At the end of ozone therapy (approx. week 16).
Change from Baseline in Postural Stability (Equilibrium Platform), (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Functional assessment of balance and Center of Pressure (CoP) displacement using specific force platforms.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Heart Rate Variability (HRV), (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Heart Rate Variability (HRV), (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Non-invasive assessment of the Autonomic Nervous System (vagal tone) by analyzing time intervals between heartbeats (RR intervals).

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At the end of ozone therapy (approx. week 16).
Changes from baseline in Hyperspectral signatures and Infrared images obtained from hands and feet at the end of follow-up, (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Assessment of the percentage of reflectance for each wavelength of the hyperspectral and infrared images obtained with specific devices.

At 12 weeks after the end of ozone therapy (approx. week 28).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At the end of ozone therapy (approx. week 16).
Changes from baseline in biochemical parameters of oxidative stress and inflammation (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Changes in serum levels of oxidative stress parameters (superoxide dismutase, glutathione, glutathione peroxidase, and free radicals) and proinflammatory cytokines.

At 12 weeks after the end of ozone therapy (approx. week 28).
Change from Baseline in Gut Microbiota Composition (at the end of ozone therapy).
기간: At the end of ozone therapy (approx. week 16).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At the end of ozone therapy (approx. week 16).
Change from Baseline in Gut Microbiota Composition (at 12 weeks after the end of ozone therapy).
기간: At 12 weeks after the end of ozone therapy (approx. week 28).

Analysis of stool samples to evaluate changes in the intestinal microbiome (in patients treated with rectal ozone).

At 12 weeks after the end of ozone therapy (approx. week 28).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 의자: Bernardino Clavo, MD, PhD, Dr. Negrín University Hospital, Las Palmas, Spain
  • 수석 연구원: Francisco Rodríguez-Esparragón, BSc, PhyD, Dr. Negrín University Hospital, Las Palmas, Spain
  • 수석 연구원: Ángeles Cánovas-Molina, RN, Dr. Negrín University Hospital, Las Palmas, Spain

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 1월 14일

기본 완료 (추정된)

2029년 12월 31일

연구 완료 (추정된)

2030년 6월 30일

연구 등록 날짜

최초 제출

2025년 12월 23일

QC 기준을 충족하는 최초 제출

2025년 12월 23일

처음 게시됨 (실제)

2026년 1월 8일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 23일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 22일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2025-642-1
  • 0177-2025-OBS (레지스트리 식별자: Identificador REEC)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

  • It will be available (after request): Individual participant data (IPD) that underlie the results reported in further articles, after deidentification
  • Data will be available after publication, ending 36 months following the article publication.
  • They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose

IPD 공유 기간

Data will be available after publication, ending 36 months following article publication.

IPD 공유 액세스 기준

They will be available for investigators whose proposed use of the data has been approved by an independent review committee identified for this purpose.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .